Moreen is a tireless advocate for our patients, ensuring that all receive timely and compassionate care.
I would like to nominate Moreen Bozier, D.N.P., for the 2022 Extraordinary Healer Award.
Moreen has worked alongside another breast medical oncologist, Dr. Joseph Sparano, and me for more than seven years, supporting our very busy breast cancer practice in an academic medical center in New York City. Our institution serves a diverse population of patients who reflect the demographics of the Bronx.
Moreen is a tireless advocate for our patients, ensuring that all receive timely and compassionate care. She plays a major role in patient education, simultaneously explaining the rationale for and toxicities of treatment and at the same time assuring scared new patients with cancer that they will be able to manage the side effects of chemotherapy.
She is central in allaying their fears as well as helping them overcome the medical mistrust that is unfortunately too common among our patient population.
In addition, Moreen has trained and mentored many nurse practitioner students and new nurse practitioners and serves as a role model for them. Several new nurses who have worked with her have commented that they aspire to be “as good as Moreen.” While working at Montefiore, Moreen also returned to school and earned her D.N.P. degree, completing an independent practice improvement project evaluating use of an educational workshop and pill diary to improve adherence to endocrine therapy in breast cancer.
In summary, I believe that Moreen Bozier is the epitome of everything that an advanced practice oncology nurse should be and is well-deserving of the Extraordinary Healer® Award.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Listen